日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Phase Ib/II Study of Zanidatamab in Combination with Tislelizumab and Chemotherapy in First-Line HER2-Positive Gastric/Gastroesophageal Junction Adenocarcinoma

Zanidatamab联合Tislelizumab和化疗一线治疗HER2阳性胃/胃食管交界处腺癌的Ib/II期研究

期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-24-4295
Lee, Keun-Wook; Bai, Li-Yuan; Jung, Minkyu; Ying, Jieer; Im, Young-Hyuck; Oh, Do-Youn; Cho, Jae Yong; Oh, Sang Cheul; Chao, Yee; Kim, Jin Won; Chen, Ye; Li, Vincent; Chen, Shengnan; Kang, Yoon-Koo
肿瘤
肿瘤免疫
HER2
发表日期：2026
文献求助 收藏

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study

IBI389（一种抗Claudin18.2×CD3双特异性抗体）在实体瘤和胃或胃食管肿瘤患者中的安全性和初步疗效结果：一项1期剂量递增和扩展研究

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-025-04597-8
Li, Xiaoyu; Dai, Ruihong; Xu, Qi; Guo, Zengqing; Hu, Changlu; Sun, Yuping; Niu, Zuoxing; Hao, Jihui; Zhang, Mingjun; Dai, Guanghai; Hua, Dong; Pan, Yueyin; Wang, Xin; Wei, Shuqing; Chen, Xiaobing; Wu, Qian; Zhang, Yulong; Zhou, Hui; Ying, Jieer; Zheng, Li; Bi, Feng
CD3
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Multi-institutional assessment of HER2 immunohistochemistry in gastric and esophagogastric junction cancer

胃癌和食管胃交界癌中HER2免疫组化的多中心评估

期刊:iScience
影响因子:4.1
doi:10.1016/j.isci.2026.115635
Zhu, Xiu; Yang, Lan; Zheng, Yangqin; Zhu, Danni; Li, Nan; Ying, Yanxia; Wang, Haiqiang; Wang, Feng; Yang, Xiaoxiao; Liu, Xing; Liao, Guanglin; Wang, Yihua; Wang, Menger; Jin, Guangjun; Zhou, Xiaoyan; Wu, Xiaoxiao; Xu, Jingjing; Wang, Ding; Liu, Zhenyuan; Liu, Yunying; Yu, Xiaozhen; Wu, Fei; Zhao, Shujue; Wang, Hui; Ying, Jieer; Cheng, Xiangdong; Wei, Qing
胃癌
免疫/内分泌
HER2
IHC
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Cadonilimab plus chemotherapy vs. PD-1 inhibitor plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer with PD-L1 combined positive score <5: a propensity-matched, retrospective cohort study

卡多尼利单抗联合化疗与PD-1抑制剂联合化疗作为PD-L1联合阳性评分<5的晚期胃癌或胃食管交界处癌一线治疗的疗效比较：一项倾向性匹配的回顾性队列研究

期刊:Journal of Gastrointestinal Oncology
影响因子:2
doi:10.21037/jgo-2025-aw-866
Zhao, Duqin; Wu, Zhongyue; Huang, Yihui; Zhang, Lei; Yuan, Xing; Zhang, Nannan; Wei, Qing; Li, Jingjing; Ying, Jieer; Xu, Qi
胃癌
肿瘤
肿瘤免疫
PD-L1
PD-1
发表日期：2026
文献求助 收藏

CLDN18.2-targeting antibody-drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial

CLDN18.2靶向抗体药物偶联物IBI343治疗晚期胃癌或胃食管交界处腺癌：一项I期试验

期刊:Nature Medicine
影响因子:50
doi:10.1038/s41591-025-03783-8
Liu, Jia; Yang, Jianwei; Sun, Yuping; Gong, Jifang; Yue, Jinbo; Pan, Yueyin; Sun, Meili; Song, Rongfeng; Xiao, Xiuying; Tazbirkova, Andrea; Ruan, Jian; Liu, Zhenyang; Liu, Zimin; Li, Zhihua; Sheng, Lili; Qin, Yanru; Ying, Jieer; Yu, Xianjun; Zhang, Jian; Mou, Yiping; Lu, Chuangxin; Chen, Ping; Li, Suyi; Li, Jie; Qu, Xiujuan; Deng, Ting; Du, Juan; Zhou, Aiping; Li, Enxiao; Yuan, Xianglin; Liang, Xinjun; Yu, Weiming; Morris, Michelle; Luo, Yang; Zhao, Xin; Guo, Yingmei; Zhou, Hui; Shen, Lin
胃癌
CLDN1
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Multi-omics analysis uncovers predictive biomarkers for the efficacy and outcomes of chemoimmunotherapy in advanced unresectable biliary tract cancers

多组学分析揭示了晚期不可切除胆道癌化疗免疫疗法疗效和预后的预测性生物标志物

期刊:BMC Medicine
影响因子:8.3
doi:10.1186/s12916-025-04263-z
Ni, Jiaojiao; Li, Chaoqun; Xu, Xiaoqing; Xu, Qi; Yin, Qian; Chen, Hanlin; Zhou, Shurui; Li, Jingjing; Zheng, Qinhong; Xie, Yanru; Hua, Hongjun; Jin, Jianying; Xie, Tieming; Zhao, Haiping; Yan, Feng; Shen, Junjun; Huang, Yihui; Zheng, Wangye; Yan, Junrong; Wu, Xiaoying; Wang, Song; Ou, Qiuxiang; Shao, Yang; Wu, Wei; Zhuo, Wei; Ying, Jieer
肿瘤
胆管癌
肿瘤免疫
免疫/内分泌
发表日期：2025
文献求助 收藏

DLAT activates EMT to promote HCC metastasis by regulating GLUT1-mediated aerobic glycolysis.

DLAT 通过调节 GLUT1 介导的有氧糖酵解激活 EMT，从而促进 HCC 转移

期刊:Molecular Medicine
影响因子:6.4
doi:10.1186/s10020-025-01125-5
Yin Qian, Yao Yinye, Ni Jiaojiao, Zhang Yiwen, Wu Jia, Zeng Hui, Wu Wei, Zhuo Wei, Ying Jieer, Li Jingjing
LAT
发表日期：2025
文献求助 收藏

First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study

帕博利珠单抗联合化疗一线治疗HER2阴性晚期胃癌：KEYNOTE-859随机3期研究的中国亚组分析

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-024-03069-4
Qin, Shukui; Bai, Yuxian; Li, Jin; Pan, Hongming; Luo, Suxia; Qu, Yanli; Ye, Feng; Yang, Lin; Liu, Tianshu; Li, Wei; Chen, Xi; Yang, Jianwei; Ying, Jieer; Lin, Xiaoyan; Zhao, Lin; Liang, Xinjun; Mao, Yixiang; Guo, Run; Zuo, Yi; Bordia, Sonal; Li, Shouguo
胃癌
肿瘤
肿瘤免疫
HER2
发表日期：2025
文献求助 收藏

SMOC2 promotes peritoneal metastasis of gastric cancer involving Wnt/β-catenin pathway modulation and inducing angiogenesis

SMOC2通过调控Wnt/β-catenin信号通路和诱导血管生成促进胃癌腹膜转移。

期刊:Clinical and Experimental Medicine
影响因子:3.5
doi:10.1007/s10238-025-01914-6
Li, Chaoqun; Yin, Luxi; Zhao, Duqin; Jiang, Yuchao; Li, Xinnuo; Yin, Qian; Xu, Jiangli; Huang, Yihui; Ni, Jiaojiao; Ying, Jieer
胃癌
SMO
肿瘤
肿瘤免疫
信号转导
Wnt/β-Catenin
血管生成
发表日期：2025
文献求助 收藏

Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study

对多纳非尼常见治疗相关不良事件及其与疗效的相关性进行分析：ZGDH3 研究的探索性分析

期刊:European Journal of Medical Research
影响因子:3.4
doi:10.1186/s40001-025-03297-6
Bi, Feng; Qin, Shukui; Gu, Shanzhi; Bai, Yuxian; Chen, Zhendong; Wang, Zishu; Ying, Jieer; Lu, Yinying; Meng, Zhiqiang; Pan, Hongming; Yang, Ping; Zhang, Helong; Chen, Xi; Xu, Aibing; Cui, Chengxu; Zhu, Bo; Wu, Jian; Xin, Xiaoli; Wang, Jufeng; Shan, Jinlu; Chen, Junhui; Zheng, Zhendong; Xu, Li; Wen, Xiaoyu; You, Zhenyu; Ren, Zhenggang; Xu, Jianming; Du, Chengyou; Fan, Qingxia; Zhang, Longzhen; Tao, Min; Jiang, Da; Wang, Senming; Chen, Yongping; Sheng, Jifang; Zhuang, Xuelong; Wu, Jun
发表日期：2025
文献求助 收藏